CYTK
Price
$56.97
Change
+$0.65 (+1.15%)
Updated
Oct 3 closing price
Capitalization
6.82B
26 days until earnings call
MNKD
Price
$5.76
Change
+$0.27 (+4.92%)
Updated
Oct 3 closing price
Capitalization
1.77B
38 days until earnings call
Interact to see
Advertisement

CYTK vs MNKD

Header iconCYTK vs MNKD Comparison
Open Charts CYTK vs MNKDBanner chart's image
Cytokinetics
Price$56.97
Change+$0.65 (+1.15%)
Volume$2.46M
Capitalization6.82B
MannKind
Price$5.76
Change+$0.27 (+4.92%)
Volume$5.13M
Capitalization1.77B
CYTK vs MNKD Comparison Chart in %
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. MNKD commentary
Oct 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 05, 2025
Stock price -- (CYTK: $56.97 vs. MNKD: $5.76)
Brand notoriety: CYTK and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 101% vs. MNKD: 112%
Market capitalization -- CYTK: $6.82B vs. MNKD: $1.77B
CYTK [@Biotechnology] is valued at $6.82B. MNKD’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • MNKD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than MNKD.

Price Growth

CYTK (@Biotechnology) experienced а +13.04% price change this week, while MNKD (@Biotechnology) price change was +4.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($6.82B) has a higher market cap than MNKD($1.77B). CYTK YTD gains are higher at: 21.110 vs. MNKD (-10.420). MNKD has higher annual earnings (EBITDA): 79.1M vs. CYTK (-504.83M). CYTK has more cash in the bank: 858M vs. MNKD (179M). MNKD has less debt than CYTK: MNKD (46.8M) vs CYTK (858M). MNKD has higher revenues than CYTK: MNKD (302M) vs CYTK (85.7M).
CYTKMNKDCYTK / MNKD
Capitalization6.82B1.77B386%
EBITDA-504.83M79.1M-638%
Gain YTD21.110-10.420-203%
P/E RatioN/A49.91-
Revenue85.7M302M28%
Total Cash858M179M479%
Total Debt858M46.8M1,833%
FUNDAMENTALS RATINGS
CYTK vs MNKD: Fundamental Ratings
CYTK
MNKD
OUTLOOK RATING
1..100
1113
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
6844
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4047
P/E GROWTH RATING
1..100
198
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for CYTK (100). This means that MNKD’s stock grew somewhat faster than CYTK’s over the last 12 months.

MNKD's Profit vs Risk Rating (44) in the Biotechnology industry is in the same range as CYTK (68). This means that MNKD’s stock grew similarly to CYTK’s over the last 12 months.

MNKD's SMR Rating (100) in the Biotechnology industry is in the same range as CYTK (100). This means that MNKD’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (40) in the Biotechnology industry is in the same range as MNKD (47). This means that CYTK’s stock grew similarly to MNKD’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MNKD (98). This means that CYTK’s stock grew significantly faster than MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKMNKD
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RERAX61.220.50
+0.82%
American Funds EUPAC R1
GGHYX40.27N/A
N/A
Invesco Health Care Y
SAREX11.56N/A
N/A
SA Real Estate Securities
MSSIX20.15N/A
N/A
Victory Trivalent International Sm-Cp R6
BLNIX13.85N/A
N/A
Meeder Balanced Institutional